Literature DB >> 9723124

Bupropion and desipramine increase dopamine transporter mRNA expression in the ventral tegmental area/substantia nigra of rat brain.

E C Petrie1, R C Veith, P Szot.   

Abstract

1. Regulation of dopamine transporter (DAT) mRNA was studied in rats treated with the DAT blocker bupropion (BUP; 15 or 30 mg/kg tid x 2d), the norepinephrine transporter blocker desipramine (DMI; 10 mg/kg/d x 2d), or saline. 2. mRNA expression was assessed via in situ hybridization histochemistry. 3. BUP and DMI both increased DAT mRNA expression in the ventral tegmental area/substantia nigra. 4. These findings suggest that DAT mRNA expression in the brain may be regulated by both noradrenergic and dopaminergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9723124     DOI: 10.1016/s0278-5846(98)00044-x

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  3 in total

1.  Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment.

Authors:  Feng Chen; Amir H Rezvani; Andrew J Lawrence
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

2.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

3.  The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat.

Authors:  Neil E Paterson; Svetlana Semenova; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2008-04-29       Impact factor: 4.530

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.